Quiz|Articles|November 26, 2025
Guess the Therapy Answer November 26, 2025
Advertisement
What autologous gene-corrected epidermal sheet therapy is FDA-approved for recessive dystrophic epidermolysis bullosa?
Answer: prademagene zamikeracel (pz-cel; marketed as Zevaskyn)
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – November 26, 2025
2
FDA Approves Itvisma, a New Intrathecal Route for Novartis’ SMA Gene Therapy
3
Sarepta's Elevidys Gets Boxed Warning for ALI and ALF
4
Guess the Therapy Answer November 26, 2025
5










































